Objectives: To assess the impact of lung resection extent on early-stage non-small cell lung cancer with a history of any cancer. Methods: Retrospective multicentric cohort study including patients with ≤2 cm pathologic size lung cancer with a history of any cancer, operated on from 2015 to 2021 across nine European centers (one per country). Overall survival (OS), disease-free survival (DFS) and lung cancer specific death (LCSD) between both groups were assessed before and after propensity score (PS) − matching. Risk factors for oncologic outcomes were analyzed using parsimonious model cox proportional hazard regression. Kaplan Meier and cumulative incidence function assessed the outcomes. Log-rank test and Gray’ test compared the groups. Linearized risk was used to assess recurrences. Results: Of the 1910 patients with early-stage lung cancer patients, 540 (28.2%) had a prior cancer. Lobectomy and segmentectomy were performed in 409 (75.7%) and 131 (24.3%) patients respectively. 5-year OS rates:lobectomy 81.5%, segmentectomy 80.8%, p =0.8; DFS: lobectomy 76.9%, segmentectomy 74.4%, p =0.6 and LCSD: lobectomy 8.0%, segmentectomy 4.9%, p =0.2. These finding were similar in the matched cohort. Locoregional recurrence (linearized risk: lobectomy 0.111, segmentectomy 0.066) and distant recurrence (linearized risk: lobectomy 0.093, segmentectomy 0.055) were not worse in the segmentectomy group. In multivariable analysis, prior cancer negatively impacted only lung cancer specific death HR:1.27 (95% CI:1.00–1.60). Conclusion: Compared to lobectomy, segmentectomy has not shown a worse oncologic outcome in patients with history of any prior cancer.
European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy / Joseph Lula, L., Costa, R., Huang, L., Rushwan, A., Domjan, M., Franssen, A.J.P.M., Weedle, R., Trabalza Marinucci, B., Forcada Barreda, C., Jasovic, C., Whooley, J., Serban Matache, R., Gökay Özgür, E., Ryan, R., Young, V., Tahiri, M., Fernandes, P., Rendina, E.A., Bekiroglu, N., De Loos, E.R., et al.. - In: LUNG CANCER. - ISSN 0169-5002. - (2026). [10.1016/j.lungcan.2026.109410]
European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy
Rita Costa;Beatrice Trabalza Marinucci;Pedro Fernandes;Erino Angelo Rendina;Alessandro Brunelli;
2026
Abstract
Objectives: To assess the impact of lung resection extent on early-stage non-small cell lung cancer with a history of any cancer. Methods: Retrospective multicentric cohort study including patients with ≤2 cm pathologic size lung cancer with a history of any cancer, operated on from 2015 to 2021 across nine European centers (one per country). Overall survival (OS), disease-free survival (DFS) and lung cancer specific death (LCSD) between both groups were assessed before and after propensity score (PS) − matching. Risk factors for oncologic outcomes were analyzed using parsimonious model cox proportional hazard regression. Kaplan Meier and cumulative incidence function assessed the outcomes. Log-rank test and Gray’ test compared the groups. Linearized risk was used to assess recurrences. Results: Of the 1910 patients with early-stage lung cancer patients, 540 (28.2%) had a prior cancer. Lobectomy and segmentectomy were performed in 409 (75.7%) and 131 (24.3%) patients respectively. 5-year OS rates:lobectomy 81.5%, segmentectomy 80.8%, p =0.8; DFS: lobectomy 76.9%, segmentectomy 74.4%, p =0.6 and LCSD: lobectomy 8.0%, segmentectomy 4.9%, p =0.2. These finding were similar in the matched cohort. Locoregional recurrence (linearized risk: lobectomy 0.111, segmentectomy 0.066) and distant recurrence (linearized risk: lobectomy 0.093, segmentectomy 0.055) were not worse in the segmentectomy group. In multivariable analysis, prior cancer negatively impacted only lung cancer specific death HR:1.27 (95% CI:1.00–1.60). Conclusion: Compared to lobectomy, segmentectomy has not shown a worse oncologic outcome in patients with history of any prior cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


